Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients

Core Insights - Chimerix, Inc. announced that the FDA has accepted its New Drug Application (NDA) for dordaviprone, aimed at treating patients with recurrent H3 K27M-mutant diffuse glioma [2] Company Summary - Chimerix, Inc. is focused on developing treatments for serious diseases, with the recent NDA acceptance indicating progress in its drug development pipeline [2]